Stemline Therapeutics, Inc. Announces Five Presentations At The American Society of Hematology Annual Meeting, Including A Clinical Update Of SL-401 In BPDCN

NEW YORK, Nov. 14, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) today announced five presentations at the 2013 American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 7-10, 2013, at the Ernest N. Morial Convention Center in New Orleans, LA. Investigators will present a clinical update of SL-401, a novel targeted therapy directed to tumor bulk and cancer stem cells (CSCs), in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), as well as preclinical data of SL-401 in additional indications including multiple myeloma and chronic eosinophilic leukemia, a rare hematologic cancer. In addition, preclinical data of SL-101, a novel antibody-drug conjugate (ADC) directed to tumor bulk and CSCs, in FLT3-ITD acute myeloid leukemia (AML) will be delivered via oral presentation.

Help employers find you! Check out all the jobs and post your resume.